A5018623286- Virus-based gene therapy research
- CAR-T cell therapy research
- Sarcoma Diagnosis and Treatment
- Cancer Research and Treatments
- RNA Interference and Gene Delivery
- Cancer-related Molecular Pathways
- Cancer Immunotherapy and Biomarkers
- Monoclonal and Polyclonal Antibodies Research
- Vascular Tumors and Angiosarcomas
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Lymphoma Diagnosis and Treatment
- Immunotherapy and Immune Responses
- Renal cell carcinoma treatment
- Pancreatic and Hepatic Oncology Research
- Ubiquitin and proteasome pathways
- Herpesvirus Infections and Treatments
- Tuberous Sclerosis Complex Research
- Corneal Surgery and Treatments
- CRISPR and Genetic Engineering
- Hemophilia Treatment and Research
- Blood Coagulation and Thrombosis Mechanisms
- Retinal Development and Disorders
- Cancer Genomics and Diagnostics
- Colorectal Cancer Treatments and Studies
- Chronic Myeloid Leukemia Treatments
A.P. Giannini Foundation
2018-2025
Sarcoma Oncology Center
2016-2025
Delta Air Lines (United States)
2018-2025
Exelixis (United States)
2021
Roche (Switzerland)
2021
Bioscience Research
2021
Genetech (Sri Lanka)
2021
Daiichi-Sankyo (South Korea)
2021
Astellas Pharma (China)
2021
Bioscience (China)
2021
Malignant perivascular epithelioid cell tumor (PEComa) is a rare aggressive sarcoma, with no approved treatment. To our knowledge, this phase II, single-arm, registration trial the first prospective clinical in disease, investigating safety and efficacy of mammalian target rapamycin inhibitor
Thirty-three adult and pediatric patients with refractory malignancies were treated escalating doses of melphalan (120-225 mg/m2 IV over 3 days) followed by reinfusion previously harvested cryopreserved autologous marrow. The hematological nonhematological toxicities the therapeutic effects this regimen evaluated. Increasing did not alter rate decline nor recovery peripheral blood counts. Granulocyte (greater than 500/microL) platelet count 20,000/microL) occurred in a median 19 (range...
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary point, may be published when key planned co-primary or secondary analyses are not yet available. Trial Updates provide an opportunity to disseminate additional results from studies, in JCO elsewhere, for which point has already been reported. nab-Sirolimus is approved United States treatment of metastatic locally advanced malignant perivascular epithelioid...
This Phase 1/2 study is based on the hypothesis that immune checkpoint inhibitors are more effective when given earlier in course of disease for advanced soft tissue sarcoma. I endpoints-maximum tolerated dose previously treated patients; II endpoints-best response, progression free survival and overall incidence adverse events untreated treatments-escalating doses trabectedin (1.0, 1.2, 1.5 mg/m2) as continuous intravenous infusion over 24 h every 3 weeks, 1 mg/kg ipilimumab intravenously...
Rexin-G, a nonreplicative pathology-targeted retroviral vector bearing cytocidal cyclin G1 construct, was tested in phase I/II study for gemcitabine-resistant pancreatic cancer. The patients received escalating doses of Rexin-G intravenously from 1 × 1011 colony-forming units (cfu) 2–3× week (dose 0–1) to 2 cfu 3× 2) 4 weeks. Treatment continued if there less than or equal grade toxicity. No dose-limiting toxicity (DLT) observed, and no DNA integration, replication-competent retrovirus...
Rexin-G, a pathotropic nanoparticle bearing cytocidal cyclin G1 construct was tested in phase I/II study for chemotherapy-resistant sarcomas and II osteosarcoma. Twenty sarcoma patients 22 osteosarcoma received escalating doses of Rexin-G intravenously from 8 × 1011 to 24 colony forming units (cfu)/cycle. Treatment continued if there ≤ grade 1 toxicity. No dose-limiting toxicity (DLT) observed, no vector DNA integration, replication-competent retrovirus (RCR) or vector-neutralizing...
Rexin-G is a replication-incompetent retroviral vector displaying cryptic SIG-binding peptide for targeting abnormal Signature (SIG) proteins in tumors and encoding dominant-negative human cyclin G1 construct. Herein we report on the safety antitumor activity of escalating doses gemcitabine-refractory pancreatic adenocarcinoma, with one 10-year survivor. For analysis (n = 20), treatment-related grade 1 adverse events included fatigue 6), chills 2), headache 1), no organ damage DLT. No...
A bystander effect is described when nontransduced or genetically unmodified cells are killed during death of modified tumor transduced with a suicide gene. The "bystander effect" greatly enhances the efficacy herpes simplex virus-thymidine kinase/ganciclovir (HSV-TK/GCV) gene therapy approach for cancer. mechanism controversial. In this study, we examined role intercellular gap junction communication (GJIC) in human gastrointestinal cells. Our results show that extent varied amongst cell...
GRP78 is a stress-inducible chaperone protein with antiapoptotic properties that overexpressed in transformed cells and under glucose starvation, acidosis, hypoxic conditions persist poorly vascularized tumors. Previously we demonstrated the Grp78 promoter able to eradicate tumors using murine immunocompetent models by driving expression of HSV-tk suicide gene. Here, through use positron emission tomography (PET) imaging, provide direct evidence spontaneous vivo activation gene driven...
The objective of this study was to determine the efficacy intraperitoneal (IP) injections a new concentrated herpes simplex thymidine kinase (HS-tk) retroviral vector and ganciclovir (GCV) for peritoneal metastases from pancreas cancer.Metastatic cancer is fatal. Gene therapy may provide novel approach disease. with adeno- or retroviral-mediated transfer HS-tk gene into tumor cells renders susceptible GCV. Intratumoral intracavity vectors have been ineffective in previous studies.Pancreatic...
Clotting factor XII (Hageman factor) contains epidermal growth (EGF)-homologous domains and is reported to be a potent mitogen for human hepatoma (HepG2) cells. In this study, we tested whether exhibits activity on several other EGF-sensitive target cells, including fetal hepatocytes, endothelial alveolar type II aortic smooth muscle We found that significantly enhanced [3H]thymidine incorporation in cells (SMCs) all tested. Tyrphostin, receptor/tyrosine kinase antagonist, inhibited both...
The amount and activity of superoxide dismutase (SOD) (EC 1.15.1.1) were measured in red cells collected from 50 white controls, 101 black patients with sickle hemoglobin (SS Hb), 12 trait, 11 other sickling hemoglobinopathies. Red normal subjects had more SOD than whites (1.77 U/mg Hb 2.96 μg/mg vs. 1.47 2.64 Hb, respectively) or blacks SS Patients severe manifestations lower levels those milder symptoms but the same enzyme protein. Individuals trait amounts activities comparable to...
Background Intratumoral injection of talimogene laherparepvec evokes a cytotoxic immune response. Therefore, the combination with trabectedin and nivolumab may have synergistic effects in advanced sarcomas. Patients methods This phase 2 trial was conducted from May 30, 2019 to January 31, 2022. Endpoints: Primary: Progression free survival rate at month 12. Secondary: Best overall response, progression 6 9 months, 6, 9, 12 incidence conversion an unresectable tumor resectable tumor, adverse...